Such a mechanism potentially affects SV breakpoints in known oncogenes (e.g., MAP3K13, MECOM and PREX2), breakpoints in genes known to be involved in oncogenic fusions (e.g., AFF3, LPP and ERG), and simple mutations in oncogenes (e.g., SSNVs in SMARCA4 and CACNA1A), see Fig. 6C, D. MAP3K13 had been shown to promote tumor growth in high MYC-expressing cells51,52, a similar context as in the OS39. This evidence concerns the gene MECOM and neoplasm.